E430029J22Rik Inhibitors
The chemical class known as E430029J22Rik Inhibitors comprises a diverse group of compounds that have the potential to inhibit E430029J22Rik through various mechanisms. These inhibitors primarily target epigenetic regulators involved in chromatin modification, influencing the structure and accessibility of the chromatin associated with E430029J22Rik. JQ1 and I-BET151, BET bromodomain inhibitors, can potentially inhibit E430029J22Rik by disrupting the binding of BET proteins to chromatin, negatively impacting its activation and functionality.
GSK126, UNC1999, and EPZ-6438, as EZH2 inhibitors, may inhibit E430029J22Rik by targeting the EZH2 histone methyltransferase, leading to alterations in chromatin structure that negatively impact E430029J22Rik activation. UNC3866 and EPZ-5676, DOT1L inhibitors, could potentially
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1, a BET bromodomain inhibitor, may inhibit E430029J22Rik by targeting the bromodomain-containing proteins. This interference can disrupt the binding of BET proteins to chromatin, potentially impacting E430029J22Rik activation and functionality. | ||||||
I-BET 151 Hydrochloride | 1300031-49-5 (non HCl Salt) | sc-391115 | 10 mg | $450.00 | 2 | |
I-BET151, another BET bromodomain inhibitor, can potentially inhibit E430029J22Rik by disrupting the interaction between BET proteins and chromatin. This interference may lead to downstream effects negatively impacting E430029J22Rik activation. | ||||||
GSK126 | 1346574-57-9 | sc-490133 sc-490133A sc-490133B | 1 mg 5 mg 10 mg | $92.00 $243.00 $306.00 | ||
GSK126, an EZH2 inhibitor, may inhibit E430029J22Rik by targeting the EZH2 histone methyltransferase. Inhibition of EZH2 can lead to alterations in chromatin structure, potentially impacting E430029J22Rik activation and contributing to its functional suppression. | ||||||
EPZ6438 | 1403254-99-8 | sc-507456 | 1 mg | $66.00 | ||
EPZ-6438, an EZH2 inhibitor, may inhibit E430029J22Rik by targeting the EZH2 histone methyltransferase. Inhibition of EZH2 can lead to alterations in chromatin structure, potentially impacting E430029J22Rik activation and contributing to its functional suppression. | ||||||
GSK-J4 | 1373423-53-0 | sc-507551 | 100 mg | $1275.00 | ||
GSK-J4, a JMJD3/UTX inhibitor, may inhibit E430029J22Rik by targeting the histone demethylases JMJD3/UTX. Inhibition of these demethylases can lead to alterations in chromatin structure, potentially impacting E430029J22Rik activation and functionality. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $179.00 $700.00 | 9 | |
UNC0642, a G9a/GLP inhibitor, can potentially inhibit E430029J22Rik by targeting the histone methyltransferases G9a/GLP. Inhibition of G9a/GLP can lead to alterations in chromatin structure, potentially impacting E430029J22Rik activation and contributing to its functional suppression. | ||||||